Benefit-Risk And Medical Costs of Rivaroxaban 15mg Versus Vitamin K Antagonists From A French Nationwide Cohort of 220,000 Patients With Non-Valvular Atrial Fibrillation

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1191
https://www.valueinhealthjournal.com/article/S1098-3015(17)31525-5/fulltext
Title : Benefit-Risk And Medical Costs of Rivaroxaban 15mg Versus Vitamin K Antagonists From A French Nationwide Cohort of 220,000 Patients With Non-Valvular Atrial Fibrillation
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31525-5&doi=10.1016/j.jval.2017.08.1191
First page : A608
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 1137
Categories :
Tags :
Regions :
ViH Article Tags :